



World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board

March 29, 2019

SAN DIEGO, March 29, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, announced that Dr. Robert Langer, co-inventor of Daré's novel, segmented intravaginal ring (IVR) drug delivery technology and one of the 10 Institute Professors at the Massachusetts Institute of Technology (MIT) joined the company's Scientific Advisory Board.

In his work at MIT, Dr. Langer's research focuses on the integration of medicine, materials science and chemical engineering. His pioneering work in biotechnology began when he joined Dr. Judah Folkman's cancer researcher lab at the Children's Hospital Boston. Their combined efforts led to the design of a novel delivery system for a tumor inhibitor using a synthetic polymer system that was directly implanted into the tumor. While at Dr. Folkman's lab, Dr. Langer pursued a second line of research to identify polymers that would permit the gradual timed release of medication within the body.

"I have a deep passion and commitment for transforming science into life-saving and life-improving inventions and I am delighted to be a member of Daré's Scientific Advisory Board," said Dr. Langer. "The polymer-based segmented IVR delivery platform is a truly innovative approach that is uniquely designed for women. I am looking forward to working closely with the scientific and medical team at Daré to help advance the many important applications of the IVR platform as well as advising on broader strategic and research initiatives across their novel women's health portfolio."

Currently, Dr. Langer is the most cited engineer in history. He has authored over 1,400 articles, and holds over 1,350 issued and pending patents worldwide. He served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.

"We are truly honored to have Dr. Langer join our distinguished board of scientific advisors," said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. "We believe Dr. Langer's contributions to science and technology are unparalleled and we feel extremely fortunate to have him advising the company on our IVR drug delivery platform as well as our other novel pipeline initiatives."

Dr. Langer has received over 220 major awards and is one of seven individuals to have received both the United States National Medal of Science, in 2006, and the United States National Medal of Technology and Innovation, in 2011. Dr. Langer also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the 2008 Millennium Prize, the world's largest technology prize. In 2012 he received the Priestley Medal, the highest award of the American Chemical Society, and in 2013 he was awarded the Wolf Prize in Chemistry. In 2015 he received the Queen Elizabeth Prize for Engineering. Dr. Langer received his Bachelor's Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Daré's product portfolio includes potential first-in-class candidates in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré's full portfolio of women's health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (<http://ir.darebioscience.com>), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (<https://darebioscience.gcs-web.com/>) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of the company's website mentioned above.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:

Alex Gray
Burns McClellan
agray@burnsmc.com

212-213-0006

OR

Media on behalf of Daré Bioscience, Inc.:

Amanda Guisbond

Canale Communications

amanda@canalecomm.com

781-405-8775

Source: Daré Bioscience



Source: Dare Bioscience, Inc.